Phenylacetic acid and arterial vascular properties in patients with chronic kidney disease stage 5 on hemodialysis therapy

Nephron - Clinical Practice

Volumn 107, Issue 1, 2007, Pages

  Scholze, Alexandra ^a   Jankowski, Vera ^a   Henning, Lars ^a   Haass, Wiltrud ^a   Wittstock, Antje ^a   Suvd Erdene, Sukhbaatar ^a   Zidek, Walter ^a   Tepel, Martin ^a   Jankowski, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arterial properties; Chronic kidney disease stage 5; Phenylacetic acid; Uremic toxins

Indexed keywords

PHENYLACETIC ACID;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIGITAL IMAGING; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HEMODIALYSIS; HUMAN; MAINTENANCE THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOELECTRIC PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; ARTERIES; FEMALE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHENYLACETATES; PROSPECTIVE STUDIES; RENAL DIALYSIS; VASOCONSTRICTION;

EID: 34548408176     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000105137     Document Type: Article

References (30)

1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295.
2. Parfrey PS: Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 2000;15(suppl 5):58-68.
3. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
4. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20:1048-1056.
5. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A, Malberti F, Spotti D: Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001;12:2411-2417.
6. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
7. 2+ ATPase in end-stage renal failure. J Am Soc Nephrol 1998;9:1249-1257.
8. Jankowski J, van der Giet M, Jankowski V, Schmidt S, Hemeier M, Mahn B, Giebing G, Tölle M, Luftmann H, Schlüter H, Zidek W, Tepel M: Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003;112:256-264.
9. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-2439.
10. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2001;103:987-992.
11. Wilson PW, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 2001;103:1529-1534.
12. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M: Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 2004;19:785-796.
13. Bell JD, Brown JCC, Sadler PJ: High resolution proton magnetic resonance studies of human cerebrospinal fluid. Clin Sci 1987;72:563-570.
14. Bodenhausen G, Kogler H, Ernst RR: Selection of coherence-transfer pathway in NMR pulse experiments. J Magn Res 1984;58:370-378.
15. Bell JD, Lee JA, Lee HJ, Sadler PJ, Wilkie DR, Woodham RH: Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure. Biochim Biophys Acta 1991;1096:101-107.
16. Takazawa K, Tanaka N, Fujita M, Matsuoka O, Saiki T, Aikawa M, Tamura S, Ibukiyama C: Assessment of vasoactive agents and vascular aging by the second derivative of photoplethysmogram waveform. Hypertension 1998;32:365-370.
17. Chowienczyk PJ, Kelly RP, MacCallum BN, Millasseau SC, Andersson TLG, Gosling RG, Ritter JM, Anggard EE: Photoplethysmographic assessment of pulse wave reflection. J Am Coll Cardiol 1999;34:2007-2014.
18. Millasseau SC, Guigui FG, Kelly RP, Prasad K, Cockcroft JR, Ritter JM, Chowienczyk PJ: Noninvasive assessment of the digital volume pulse: comparison with the peripheral pressure pulse. Hypertension 2000;36:952-956.
19. Millasseau SC, Kelly RP, Ritter JM, Chowienczyk PJ: Determination of age-related increases in large artery stiffness by digital pulse contour analysis. Clin Sci 2002;103:371-377.
20. Woodmann RJ, Watts GF, Kingwell BA, Dart AM: Interpretation of the digital volume pulse: its relationship with large and small artery compliance. Clin Sci (Lond) 2003;104:283-285.
21. Avolio A: The finger volume pulse and assessment of arterial properties. J Hypertens 2002;20:2341-2343.
22. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M: Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004;109:369-374.
23. Burkert A, Scholze A, Tepel M: Non-invasive continuous monitoring of digital pulse waves during hemodialysis. ASAIO J 2006;52:174-179.
24. Scholze A, Burkert A, Mardanzai K, Suvd-Erdene S, Hausberg M, Zidek W, Tepel M: Increased arterial vascular tone during the night in patients with essential hypertension. J Hum Hypertens 2007;21:60-67.
25. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C, Ward J: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 1984;310:1630-1634.
26. Mendenhall CL, Rouster S, Marshall L, Weesner R: A new therapy for portal systemic encephalopathy. Am J Gastroenterol 1986;81:540-543.
27. Sharma RP, Faull K, Javaid JI, Davis JM: Cerebrospinal fluid levels of phenylacetic acid in mental illness: behavioral associations and response to neuroleptic treatment. Acta Psychiatr Scand 1995;91:293-298.
28. Samid D, Shack S, Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288-2295.
29. Thibout D, Kraemer M, Di Benedetto M, Saffar L, Gattegno L, Derbin C, Crepin M: Sodium phenylacetate (NaPa) induces modifications of the proliferation, the adhesion and the cell cycle of tumoral epithelial breast cells. Anticancer Res 1999;19:2121-2126.
30. Kebebew E, Wong MG, Siperstein AE, Duh QY, Clark OH: Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function. J Clin Endocrinol Metab 1999;84:2840-2847.